Nutritional science central to Elanco, Purdue partnershipFebruary 13, 2020Elanco Animal Health has announced a five-year collaborative research agreement with Purdue University and Purdue Research Foundation (PRF) intended to streamline solutions for animal health-related challenges.
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
Elanco unloads flea treatment for $95 millionJanuary 21, 2020Elanco Animal Health has just divested its proprietary flea treatment tablets in an all-cash deal, totaling $95 million.
Elanco divests canine ear treatment in $135-million dealJanuary 6, 2020A major player in the animal health industry has just unloaded its proprietary treatment for canine otitis externa in an all-cash deal, totaling $135 million.
Aquaculture R&D firm acquires Elanco facilityDecember 24, 2019Aligning with its international restructuring plans, Elanco Animal Health has sold its aqua research and development (R&D) facility in Victoria, Prince Edward Island (PEI), Canada.
Elanco to cut 250 jobsOctober 2, 2019Elanco Animal Health says it is eliminating approximately 250 jobs across multiple locations and departments in an effort to “enhance productivity and drive efficiency.”
Elanco acquires Bayer's animal health division in $7.6-billion dealAugust 20, 2019Following months of speculation, two major industry players have finalized a deal, resulting in the creation of the second-largest animal health company in the world.
Elanco acquires food animal vaccine start-upAugust 13, 2019Elanco Animal Health has purchased Prevtec Microbia, a biotechnology company specializing in the development of vaccines to help prevent bacterial diseases in food animals.
Elanco and Aratana Therapeutics finalize deal to mergeJuly 18, 2019Elanco Animal Health has acquired Aratana Therapeutics. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. "Aratana's strong position in the specialty market—with its current portfolio and pipeline—complements Elanco's field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands," says Jeff Simmons, president and chief executive officer of Elanco. "This deal furthers Elanco's value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians and pet owners." Aratana produces Galliprant, a canine NSAID for osteoarthritis for which Elanco has had the exclusive rights to develop, manufacture, and commercialize since 2016. Aratana also contributes two additional products to Elanco's portfolio: Entyce, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Further, Aratana's research and development pipeline will contribute to Elanco's efforts to sustain the introduction of novel and innovative companion animal therapeutics. As a result of the acquisition, Elanco says it is forming a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. This specialty sales force will …
Bayer and Elanco rumored to be mergingJuly 10, 2019A significant animal health merger might be in the works between pharmaceutical company Bayer and Elanco Animal Health.
Service dogs can lead to a better life for ownersMay 21, 2019Service dogs improve the quality of life for their owners, according to a new study. Due to an increase in demand for service dogs, researchers at Purdue University College of Veterinary Medicine determined a need for using standardized measures to look at the relationship between the human-animal bond and psychosocial outcomes among people with service dogs over a four-year period. Elanco Animal Health funded the study. "Our goal was to apply strong science in quantifying the effects these dogs can have on well-being," says Maggie O'Haire, PhD, associate professor of human-animal interaction at Purdue University. "The research also reveals the distinctive role a service dog may have in the lives of the families of those individuals." Of the 154 recruited participants, 97 people who used a mobility or medical service dog displayed better psychosocial health, including higher levels of social and emotional functioning, and better functioning at work and/or school in comparison to the 57 who were on a waiting list. "Previous smaller and chiefly qualitative studies have found preliminary evidence service dogs can have psychosocial benefits among individuals with physical disabilities, but the research has been limited," said Tony Rumschlag, DVM, director, consulting veterinarians, U.S. companion animal business …
